Sendai virus envelopes can mediate Epstein-Barr virus binding to and penetration into Epstein-Barr virus receptor-negative cells.
Epstein-Barr virus (EBV) receptor-negative cells were treated with UV-inactivated Sendai virus (SV) or with reconstituted SV envelopes having a low hemolytic activity and then assayed for EBV binding or for susceptibility to EBV infection. EBV binding was assessed by using both unlabeled and fluoresceinated EBV preparations. It was found that SV or SV envelope treatment renders these cells able to bind EBV. Various experiments were performed to clarify the mechanism of this SV-induced binding. The EBV receptor-negative 1301 cells were treated with SV either at 0 degrees C or at both 0 and 37 degrees C successively and then examined for EBV binding at 0 degrees C. It was thus found that when SV treatment was performed exclusively at 0 degrees C, the target cells showed higher fluorescence intensity after their incubation with fluoresceinated EBV. In addition, Clostridium perfringens neuraminidase treatment of 1301 cells did not induce any EBV binding to these cells. These data indicate that EBV binding is not due to the disturbance of the cell membrane by SV envelope fusion or to the uncovering of EBV binding sites on the cells after the enzymatic action of SV neuraminidase. Moreover, bound EBV was partly eluted from SV-treated 1301 cells at 37 degrees C, and the treatment of EBV with C. perfringens neuraminidase inhibited its SV-mediated binding. These data indicate that EBV binds to the hemagglutinin-neuraminidase of SV on the target cell surface and that a fraction of the bound EBV becomes irreversibly associated with the SV-treated cell membrane. Our data also show that EBV can penetrate into 1301 cells which have incorporated SV envelopes into their membrane, as demonstrated by the induction of the EBV-determined nuclear antigen by B95-8 EBV in SV envelope-treated 1301 cells.
D000818:Animals; D002478:Cells, Cultured; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D009439:Neuraminidase / Q000494:pharmacology; D010222:Parainfluenza Virus 1, Human / Q000378:metabolism*; D017464:Receptors, Complement 3d; D011952:Receptors, Concanavalin A / Q000187:drug effects / Q000378:metabolism; D011991:Receptors, Virus / Q000187:drug effects / Q000378:metabolism*; D013696:Temperature
D017464:Receptors, Complement 3d; D011952:Receptors, Concanavalin A; D011991:Receptors, Virus; D009439:Neuraminidase